Intelerad Medical Systems launched its new Tomosynthesis Module. Integrated directly into Intelerad’s InteleViewer, the module eliminates the need for dedicated workstations, allowing practices to easily open new revenue streams, while enhancing radiologists’ workflows by allowing them to read tomosynthesis studies from their main workstation. 

Although most accountable care organizations have the health information technology to improve clinical quality, poor interoperability across systems and providers remains a barrier, according to an ACO survey conducted by Premier Inc. and the eHealth Initiative. 

New technology and better screening strategies can lower the rate of false-positive results, which impose a substantial financial and psychological burden on women. The many misperceptions about breast cancer screening options and risks, the benefits and costs of screening, and the need for new approaches and better education are discussed in a series of articles in a supplement to Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The supplement is available free on the Journal of Women's Health website at http://online.liebertpub.com/toc/jwh/23/S1.


August 14, 2014 — Mammography-detected breast cancer is associated with a shift to earlier stage diagnosis in older women, subsequently reducing the rate of more advanced, difficult-to-treat cases, according to a new study published online in the journal Radiology. Researchers said the findings lend support to regular mammography screening in women ages 75 and older.

September 30, 2014 — CIRS recently released a phantom for evaluating MRI (magnetic resonance imaging) distortion in stereotactic radiosurgery (SRS) treatment planning.

September 30, 2014 — More than 60 patient advocacy and medical organizations have joined a coalition headed by the Lung Cancer Alliance, the American College of Radiology (ACR) and the Society of Thoracic Surgeons (STS), in urging Medicare to cover low-dose computed tomography (LDCT) screening for beneficiaries at high risk for lung cancer.

September 30, 2014 — The American College of Cardiology (ACC), along with eight partnering societies, released the first appropriate use criteria (AUC) for suspected heart disease in pediatric patients.

The U.S. Food and Drug Administration has allowed marketing of the NephroCheck test, a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury (AKI) in the 12 hours following the administration of the test.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now